NasdaqGM:CHRSBiotechs
A Look At Coherus Oncology (CHRS) Valuation After Its US$64.9 Million Follow On Equity Offering
Follow on offering sets the stage
Coherus Oncology (CHRS) has filed a follow on equity offering of about US$64.9 million through an at the market program. This is a material move that directly affects funding plans and existing shareholders.
See our latest analysis for Coherus Oncology.
The follow on offering arrives after a sharp rebound in sentiment, with a 1 month share price return of 53.73% and year to date share price return of 50.37%. However, the 5 year total shareholder return of an...